This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Global X Launches GNOM ETF to Tap Booming Genomics Space
by Sweta Jaiswal, FRM
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
Why Is Ultragenyx (RARE) Up 12.4% Since Last Earnings Report?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.
Will Ultragenyx (RARE) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
by Zacks Equity Research
Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
by Zacks Equity Research
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) submitts regulatory filings in Canada, Brazil and Colombia for Crysvita for the treatment of XLH.
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.31% and 5.01%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
by Zacks Equity Research
Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Ultragenyx (RARE) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Reports Top-line Data From Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) reports encouraging top-line data from two cohorts of the study evaluating its adeno-associated virus ("AAV") gene therapy candidate -- DTX301.
Ultragenyx's Shares Surge More Than 80% in the Year So Far
by Zacks Equity Research
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data
by Zacks Equity Research
Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.
Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval
by Zacks Equity Research
Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.
Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
by Zacks Equity Research
Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 10.95% and 180.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.
Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.
Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
by Zacks Equity Research
Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.